Previous 10 | Next 10 |
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Last Wednesday, we finally got the announcement: Elon Musk had sold another $3.6 billion of Tesla (NASDAQ: TSLA ) stock earlier in the week. (SEC filings tend to lag several days behind transactions). Such a sale had ...
MIAMI, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, today announced that Company leadership will participate in three upcoming investor conferen...
Longeveron Inc. (LGVN) Q3 2022 Earnings Conference Call November 14, 2022 08:30 a.m. ET Company Representatives Dr. Chris Min - Interim Chief Executive Officer, Chief Medical Officer Dr. Joshua Hare - Co-Founder, Chief Science Officer, Chairman James Clavijo - Ch...
Longeveron press release ( NASDAQ: LGVN ): Q3 GAAP EPS of -$0.25 misses by $0.03 . Revenue of $0.3M (+50.0% Y/Y) beats by $0.2M . Cash and short-term investments was $22.3M and $35.0M as of September 30, 2022, and December 31, 2021, respectively. Financ...
-- Achieved key clinical and regulatory milestones across clinical pipeline, including the completion of enrollment in Longeveron’s Phase 2a trial for Alzheimer’s Disease -- -- Conference call scheduled for 8:30 a.m. ET today -- MIAMI, Nov. 14, 2022 (GLOBE NEWS...
MIAMI, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, today announced the completion of enrollment in its Phase 2a trial of Lomecel-B TM in pa...
MIAMI, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, today announced that the Company will release its third quarter 2022 financial results on Mo...
Summary Today, we take our first look at Longeveron Inc., a small clinical-stage biotech concern. The company is targeting multiple disease indications within its pipeline, including Alzheimer's. An investment analysis follows in the paragraphs below. For...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips In October 2021, I made a big call on Longeveron (NASDAQ: LGVN ) stock, a biotech firm working on a promising Alzheimer’s therapy. Within six weeks, shares had risen over 11x… a stunning 1,000% return! ...
MIAMI, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, announced today that Chris Min, M.D., Ph.D., Interim Chief Executive Officer, and Chief Medi...
News, Short Squeeze, Breakout and More Instantly...
Longeveron (NASDAQ: LGVN) , a clinical-stage, regenerative-medicine biotechnology company developing cellular therapies for rare, life-threatening and chronic aging-related conditions, has closed on its previously announced registered direct offering. The offering, which was priced at-the-market ...
MIAMI, July 19, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or the “Company”), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today ann...
A look at the top 10 most actives in the United States Onconetix Inc. (ONCO) rose 113.3% to $0.3178 on volume of 162,323,665 shares NVIDIA Corporation (NVDA) rose 0.8% to $118.92 on volume of 44,858,282 shares Maxeon Solar Technologies Ltd. (MAXN) rose 8.5% to $0.2648 on volume of 43,008,...